Quarterly Device Clearance Digest — Q3 2026

LED masks and intense pulsed light (IPL) devices account for roughly half of Q3's 510(k) approvals, including LED Light Therapy Mask (Guangdong Newdermo), LED Neck Beauty Mask (Shenzhen Kaiyan), CurrentBody Skin LED Multi Light Therapy Mask (The Beauty Tech Group), and Intense Pulsed Light Therapy Device (Sanhe LEFIS). These are substantially equivalent to existing predicate devices, meaning lower regulatory friction and faster market entry. For practices, the proliferation signals commoditization: margins on light-based treatments may compress as supply increases. Practices should evaluate whether their current light platform justifies retention or whether newer entrants offer better consumable pricing or clinical outcomes.

Radiofrequency (RF) systems cleared this quarter include MILAN System (Lumenis), VIVA combo RF System (Starmed), and CoolSeal Generator® (Hologic). Alongside these, Renuvion (helium-plasma) generated three SEC filings from Apyx Medical, signaling active corporate development and likely continued investment in the platform. RF and plasma devices command higher per-treatment pricing and lower consumable burn than light therapies, making them attractive for practices seeking margin stability. However, Apyx's frequent filings warrant monitoring: corporate restructuring can affect service, training, and consumable supply chains.

Q3 saw four laser-based 510(k) clearances—PICOSURE WORKSTATION (Cynosure), LumiGlam Laser System (Beijing Sano), LASEmaR 1500 (Eufoton), and an active Phase 4 trial on skin resurfacing (Bausch Health). However, an Erchonia laser trial for skin laxity was terminated, suggesting that not all laser applications meet clinical endpoints. Practices considering laser purchases should scrutinize published outcomes and trial data rather than relying on clearance alone. Clearance means safety and predicate equivalence, not superiority.

HydraFacial (The Beauty Health Company) filed two material events; Apyx Medical (Renuvion) filed three; Bausch Health (Solta: Thermage, Fraxel, Clear+Brilliant) filed three. These filings often signal M&A activity, debt restructuring, or strategic pivots. For practices with HydraFacial or Solta devices, frequent corporate filings raise questions about consumable pricing, support continuity, and potential spin-offs. Practices should review vendor contracts for price-lock clauses and service guarantees, and consider diversifying device portfolios to reduce single-vendor risk.

Hemolase Fiber (Micro-Energy Medical) and Veineo System (F Care Systems) both cleared for vascular and vein treatment. These represent niche but growing revenue streams for practices offering comprehensive body aesthetics. Both are substantially equivalent clearances, meaning they follow established safety profiles. Vascular treatments often command premium pricing and have strong patient demand; practices without vein/vascular capability may see this as an expansion opportunity, though training and credentialing requirements apply.

Clearance ≠ superiority. A 510(k) means a device is as safe and effective as an existing predicate; it does not mean it outperforms competitors. Evaluate devices on clinical outcomes, consumable cost per treatment, vendor stability, and service support—not just regulatory status. With 16 clearances in one quarter, market saturation is real. Practices should prioritize devices with strong clinical data, stable vendors, and clear ROI timelines. If a vendor is filing frequent SEC events, request transparency on pricing and support roadmaps before committing capital.